Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELEMENT 5: Basaglar vs Lantus in Type 2 Diabetes
NCT02302716Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2014
- Primary completion
- Jul 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
A Phase 3 trial of insulin glargine in type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Started Dec 2014; status: completed.
02
Drugs
insulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02302716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02302716.